Ghent University Academic Bibliography

Advanced

Evaluation of a MOMP-based DNA vaccine against C. trachomatis serovar E infection in a pig model

Katelijn Schautteet UGent, Edith Stuyven UGent, Delphine Sylvie Anne Beeckman UGent, Marianne Carlon, Sofie Van Acker, Koen Chiers UGent, Eric Cox UGent and Daisy Vanrompay UGent (2010) Amsterdam Chlamydia Meeting, 7th Annual, Abstracts.
abstract
Chlamydia trachomatis is a bacterial pathogen that is the leading cause of bacterial “Sexual Transmitted Disease” (STD) in developing countries. Most often the infection is asymptomatic. However, if the infection remains untreated, it often results in pelvic inflammatory disease (PID), ectopic pregnancy, chronic pelvic pain in women, urethritis and epididymitis in men or infant pneumonia. The infection can easily be treated with antibiotics, but in most cases damage is already done before the bacterium is noticed. Immunization is considered to be the best approach to reduce C. trachomatis infections. However, so far no vaccine is available. In this study, plasmid DNA (pWRG7079::MOMP) expressing the major outer membrane protein of a human Chlamydia trachomatis serovar E strain was tested for the ability to induce an immune response and protect against experimental genital infection with the same serovar. The vaccine was tested in pigs, as they are genetically, physiologically and immunologically related to humans and suitable for studying C. trachomatis infection of the genital system. To increase the immune response, GM-CSF and LTa+LTb were used as adjuvants. GM-CSF was administered seven days before immunization, while the other adjuvants were administered together with the vaccine. Ten pigs were randomly divided into two groups. One group received an intravaginal primo-vaccination and a booster of 500 µg pWRG7079::MOMP, while the other group received the placebo vaccine pWRG7079. All animals were challenged intravaginally with 108 TCID50 of C. trachomatis serovar E. Pigs immunized with the DNA vaccine showed significantly less macroscopic lesions, vaginal excretion and chlamydial replication in the genital tract, as compared to placebo-vaccinated controls. A clear relationship could be detected between high stimulation indices in the lymphocyte proliferation assays and better protection. However, the infection could not be completely cleared.
Please use this url to cite or link to this publication:
author
organization
year
type
conference
publication status
published
subject
in
Amsterdam Chlamydia Meeting, 7th Annual, Abstracts
conference name
7th Annual Amsterdam Chlamydia Meeting
conference location
Amsterdam, The Netherlands
conference start
2010-12-17
conference end
2010-12-17
language
English
UGent publication?
yes
classification
C3
copyright statement
I have transferred the copyright for this publication to the publisher
id
1089592
handle
http://hdl.handle.net/1854/LU-1089592
date created
2010-12-20 10:03:04
date last changed
2010-12-20 15:38:00
@inproceedings{1089592,
  abstract     = {Chlamydia trachomatis is a bacterial pathogen that is the leading cause of bacterial {\textquotedblleft}Sexual Transmitted Disease{\textquotedblright} (STD) in developing countries. Most often the infection is asymptomatic. However, if the infection remains untreated, it often results in pelvic inflammatory disease (PID), ectopic pregnancy, chronic pelvic pain in women, urethritis and epididymitis in men or infant pneumonia. The infection can easily be treated with antibiotics, but in most cases damage is already done before the bacterium is noticed. Immunization is considered to be the best approach to reduce C. trachomatis infections. However, so far no vaccine is available. 
In this study, plasmid DNA (pWRG7079::MOMP) expressing the major outer membrane protein of a human Chlamydia trachomatis serovar E strain was tested for the ability to induce an immune response and protect against experimental genital infection with the same serovar. The vaccine was tested in pigs, as they are genetically, physiologically and immunologically related to humans and suitable for studying C. trachomatis infection of the genital system. To increase the immune response, GM-CSF and LTa+LTb were used as adjuvants. GM-CSF was administered seven days before immunization, while the other adjuvants were administered together with the vaccine. Ten pigs were randomly divided into two groups. One group received an intravaginal primo-vaccination and a booster of 500 {\textmu}g pWRG7079::MOMP, while the other group received the placebo vaccine pWRG7079. All animals were challenged intravaginally with 108 TCID50 of C. trachomatis serovar E. Pigs immunized with the DNA vaccine showed significantly less macroscopic lesions, vaginal excretion and chlamydial replication in the genital tract, as compared to placebo-vaccinated controls. A clear relationship could be detected between high stimulation indices in the lymphocyte proliferation assays and better protection. However, the infection could not be completely cleared.},
  author       = {Schautteet, Katelijn and Stuyven, Edith and Beeckman, Delphine Sylvie Anne and Carlon, Marianne  and Van Acker, Sofie and Chiers, Koen and Cox, Eric and Vanrompay, Daisy},
  booktitle    = {Amsterdam Chlamydia Meeting, 7th Annual, Abstracts},
  language     = {eng},
  location     = {Amsterdam, The Netherlands},
  title        = {Evaluation of a MOMP-based DNA vaccine against C. trachomatis serovar E infection in a pig model},
  year         = {2010},
}

Chicago
Schautteet, Katelijn, Edith Stuyven, Delphine Sylvie Anne Beeckman, Marianne Carlon, Sofie Van Acker, Koen Chiers, Eric Cox, and Daisy Vanrompay. 2010. “Evaluation of a MOMP-based DNA Vaccine Against C. Trachomatis Serovar E Infection in a Pig Model.” In Amsterdam Chlamydia Meeting, 7th Annual, Abstracts.
APA
Schautteet, K., Stuyven, E., Beeckman, D. S. A., Carlon, M., Van Acker, S., Chiers, K., Cox, E., et al. (2010). Evaluation of a MOMP-based DNA vaccine against C. trachomatis serovar E infection in a pig model. Amsterdam Chlamydia Meeting, 7th Annual, Abstracts. Presented at the 7th Annual Amsterdam Chlamydia Meeting.
Vancouver
1.
Schautteet K, Stuyven E, Beeckman DSA, Carlon M, Van Acker S, Chiers K, et al. Evaluation of a MOMP-based DNA vaccine against C. trachomatis serovar E infection in a pig model. Amsterdam Chlamydia Meeting, 7th Annual, Abstracts. 2010.
MLA
Schautteet, Katelijn, Edith Stuyven, Delphine Sylvie Anne Beeckman, et al. “Evaluation of a MOMP-based DNA Vaccine Against C. Trachomatis Serovar E Infection in a Pig Model.” Amsterdam Chlamydia Meeting, 7th Annual, Abstracts. 2010. Print.